Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
CAMBRIDGE, Mass., Jan. 03, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President and CEO, will present at the 35th Annual J. P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 10th at 3:00 p.m. PT (6:00 p.m. ET).
Following the presentation, management will participate in a question and answer session at 3:30 p.m. PT (6:30 p.m. ET).
The webcast of the presentation and Q&A session will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
